Unknown OBSERVATIONAL NCT04293445

Asthma: Phenotyping Exacerbations 2 (APEX 2)

Phenotyping Asthma Exacerbations: A Longitudinal Cohort Study 2

Sponsor: AstraZeneca

Conditions ASTHMA

Interventions spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab

Updated 6 times since 2020 Last updated: Apr 28, 2021 Started: Nov 22, 2019 Primary completion: Jul 31, 2022 Completion: Jul 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on ASTHMA, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
May 2023 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
May 2021 — May 2023 [monthly]

Recruiting
Jan 2021 — May 2021 [monthly]

Recruiting

▶ Show 1 earlier version

Apr 2020 — Jan 2021 [monthly]

Recruiting

First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
University of Nottingham

Data source: University of Nottingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom